keyword
MENU ▼
Read by QxMD icon Read
search

Cancer kidney

keyword
https://www.readbyqxmd.com/read/29932968/time-trends-in-the-prevalence-of-cancer-and-non-cancer-diseases-among-older-u-s-adults-medicare-based-analysis
#1
Igor Akushevich, Julia Kravchenko, Arseniy P Yashkin, Anatoliy I Yashin
Longer lifespan is accompanied by a larger number of chronic diseases among older adults. Because of a growing proportion of older adults in the U.S., this brings the problem of age-related morbidity to the forefront as a major contributor to rising medical expenditures. We evaluated 15-year time trends (from 1998 to 2013) in the prevalence of 48 acute and chronic non-cancer diseases and cancers in older U.S. adults aged 65+ and estimated the annual percentage changes of these prevalence trends using SEER-Medicare and HRS-Medicare data...
June 19, 2018: Experimental Gerontology
https://www.readbyqxmd.com/read/29930748/serum-levels-of-soluble-urokinase-plasminogen-activator-receptor-supar-predict-outcome-after-resection-of-colorectal-liver-metastases
#2
Sven H Loosen, Frank Tacke, Marcel Binnebosel, Catherine Leyh, Mihael Vucur, Florian Heitkamp, Wenzel Schoening, Tom F Ulmer, Patrick H Alizai, Christian Trautwein, Alexander Koch, Thomas Longerich, Christoph Roderburg, Ulf P Neumann, Tom Luedde
Background: In colorectal cancer (CRC), the liver is the most common site of metastasis. Surgical resection represents the standard therapy for patients with colorectal liver metastases (CRLM). However, 5-year survival rates after resection do not exceed 50%, and despite existing preoperative stratification algorithms it is still debated which patients benefit most from surgical treatment. The soluble urokinase plasminogen activator receptor (suPAR) has recently evolved as a promising biomarker for distinct clinical conditions...
June 5, 2018: Oncotarget
https://www.readbyqxmd.com/read/29928489/smad-proteins-directly-suppress-pax2-transcription-downstream-of-transforming-growth-factor-beta-1-tgf-%C3%AE-1-signalling-in-renal-cell-carcinoma
#3
Gagandeep Kaur, Caiyun Grace Li, Andrew Chantry, Cherie Stayner, Julia Horsfield, Michael R Eccles
Canonical TGF-β1 signalling promotes tumor progression by facilitating invasion and metastasis, whereby release of TGF-β1, by (for example) infiltrating immune cells, induces epithelial to mesenchymal transition (EMT). PAX2, a member of the Paired box family of transcriptional regulators, is normally expressed during embryonic development, including in the kidney, where it promotes mesenchymal to epithelial transition (MET). PAX2 expression is silenced in many normal adult tissues. However, in contrast, PAX2 is expressed in several cancer types, including kidney, prostate, breast, and ovarian cancer...
June 1, 2018: Oncotarget
https://www.readbyqxmd.com/read/29928482/klotho-inhibits-egf-induced-cell-migration-in-caki-1-cells-through-inactivation-of-egfr-and-p38-mapk-signaling-pathways
#4
Mehdi Dehghani, Reynolds K Brobey, Yue Wang, Glauco Souza, Robert J Amato, Kevin P Rosenblatt
Klotho is a single-pass transmembrane protein with documented anti-cancer properties. Recent reports have implicated Klotho as an inhibitor of transforming growth factor β1 induced cell migration in renal fibrosis. Overexpression of epidermal growth factor receptor (EGFR) is known to promote tumor initiation and progression in clear-cell renal cell carcinoma (cRCC). We tested our hypothesis that Klotho inhibits EGF-mediated cell migration in cRCC by interfering with the EGFR signaling complex and mitogen-activated protein kinase (MAPK) pathways...
June 1, 2018: Oncotarget
https://www.readbyqxmd.com/read/29928383/research-progress-on-common-adverse-events-caused-by-targeted-therapy-for-colorectal-cancer
#5
REVIEW
Bo Zhang, Chenyan Fang, Dehou Deng, Liang Xia
As targeted drug therapy is increasingly applied in the treatment of colon cancer, understanding and managing the adverse reactions of patients is becoming increasingly important. The present review examines the mechanisms of and adverse reactions to the most commonly used targeted drugs for colon cancer, and discusses methods of coping with these adverse reactions. Approved targeted drugs for metastatic colon cancer include monoclonal antibodies targeting vascular endothelial growth factor (VEGF), including bevacizumab, ziv-aflibercept and regorafenib, and monoclonal antibodies targeting epithelial growth factor receptor (EGFR), including cetuximab and panitumumab...
July 2018: Oncology Letters
https://www.readbyqxmd.com/read/29928324/low-tumor-glutathione-level-as-a-sensitivity-marker-for-glutamate-cysteine-ligase-inhibitors
#6
Satoru Nishizawa, Hideo Araki, Yoshinori Ishikawa, Satoshi Kitazawa, Akito Hata, Tomoyoshi Soga, Takahito Hara
Previous metabolomic analyses of cancer have revealed elevated glutathione levels in tumors. An inhibitor of cystine uptake was identified to suppress glutathione biosynthesis, leading to ferroptosis, a novel iron-dependent form of cell death that differs from apoptosis and necrosis. Glutamate-cysteine ligase (GCL) is the rate-limiting enzyme in the glutathione biosynthesis pathway. Buthionine sulfoximine (BSO), a GCL inhibitor, has previously demonstrated limited clinical benefits. Therefore, selecting patients who respond well to the inhibitor is a key approach for successful future drug development...
June 2018: Oncology Letters
https://www.readbyqxmd.com/read/29928155/malignant-mixed-epithelial-and-stromal-tumour-of-the-kidney-a-case-report-and-a-literature-review
#7
Arnas Bakavičius, Marija Barisienė, Marius Snicorius, Dileta Valančienė, Darius Dasevičius, Algirdas Žalimas, Robertas Kvaščevičius, Henrikas Ramonas, Vitalijus Sokolovas, Feliksas Jankevičius
Introduction: Mixed epithelial and stromal tumour of the kidney (MEST) is a rare and distinctive neoplasm accounting for 0.2% of all renal cancers. Most of these tumours behave in a benign fashion but 13 cases with malignant transformation have already been reported. We present the first case of an extremely aggressive MEST with rapid recurrence after radical treatment, demonstrating objective response to chemotherapy. Case presentation: A 31-year-old female presented to the hospital complaining of gross hematuria...
2018: Acta Medica Lituanica
https://www.readbyqxmd.com/read/29923174/circulating-tumor-dna-analysis-enables-molecular-characterization-of-pediatric-renal-tumors-at-diagnosis
#8
Irene Jiménez, Mathieu Chicard, Léo Colmet-Daage, Nathalie Clément, Adrien Danzon, Eve Lapouble, Gaelle Pierron, Mylène Bohec, Sylvain Baulande, Dominique Berrebi, Paul Fréneaux, Aurore Coulomb, Louise Galmiche-Rolland, Sabine Sarnacki, Georges Audry, Pascale Philippe-Chomette, Hervé J Brisse, François Doz, Jean Michon, Olivier Delattre, Gudrun Schleiermacher
Circulating tumor DNA (ctDNA) is a powerful tool for the molecular characterization of cancer. The most frequent pediatric kidney tumors (KT) are Wilms' tumors (WT), but other diagnoses may occur. According to the SIOP strategy, in most countries pediatric KT have a presumptive diagnosis of WT if they are clinically and radiologically compatible. The histologic confirmation is established after post-chemotherapy nephrectomy. Thus, there is a risk for a small fraction of patients to receive neoadjuvant chemotherapy that is not adapted to the disease...
June 19, 2018: International Journal of Cancer. Journal International du Cancer
https://www.readbyqxmd.com/read/29922818/representation-of-patients-with-chronic-kidney-disease-in-trials-of-cancer-therapy
#9
Abhijat Kitchlu, Joshua Shapiro, Eitan Amir, Amit X Garg, S Joseph Kim, Ron Wald, Ziv Harel
No abstract text is available yet for this article.
June 19, 2018: JAMA: the Journal of the American Medical Association
https://www.readbyqxmd.com/read/29922090/extramedullary-hematopoiesis-secondary-to-malignant-solid-tumors-a-case-report-and-literature-review
#10
Youting Bao, Zhichao Liu, Meiying Guo, Butuo Li, Xindong Sun, Linlin Wang
Extramedullary hematopoiesis (EMH) usually occurs in hematological disease, but more rarely develops in cases of malignant solid tumors. Due to its features on computed tomography (CT) and magnetic resonance imaging (MRI) that are atypical, EMH in tumor patients might easily be misdiagnosed as metastasis leading to the improper TNM staging and inappropriate therapy. Here, we reported the first case of pleural EMH occurring in a patient with esophageal carcinoma whose pleural lesion was first diagnosed as metastasis and confirmed EMH after the needle biopsy...
2018: Cancer Management and Research
https://www.readbyqxmd.com/read/29921799/nutritional-requirements-of-lung-transplant-recipients-challenges-and-considerations
#11
REVIEW
Valerie Jomphe, Larry C Lands, Genevieve Mailhot
An optimal nutritional status is associated with better post-transplant outcomes and survival. Post-lung transplant nutrition management is however particularly challenging as lung recipients represent a very heterogeneous group of patients in terms of age, underlying diseases, weight status and presence of comorbidities. Furthermore, the post-transplant period encompasses several stages characterized by physiological and pathophysiological changes that affect nutritional status of patients and necessitate tailored nutrition management...
June 19, 2018: Nutrients
https://www.readbyqxmd.com/read/29921544/management-of-localised-prostate-cancer-in-kidney-transplant-patients-a-systematic-review-from-the-eau-guidelines-on-renal-transplantation-panel
#12
REVIEW
Vital Hevia, Romain Boissier, Óscar Rodríguez-Faba, Claire Fraser-Taylor, Rhana Hassan-Zakri, Enrique Lledo, Heinz Regele, Klemens Buddde, Arnaldo Figueiredo, Jonathon Olsburgh, Alberto Breda
CONTEXT: Cancer development after kidney transplant (KT) has become a major problem, and currently, it is one of the primary causes of death in this population. Urological cancers after KT such as prostate cancer (PCa) have also increased, partly due to the increasing age of recipients and prolonged survival. PCa is the second most commonly diagnosed cancer in men, accounting for 15% of all cancers. Managing localised PCa after KT remains challenging because of treating an immunosuppressed patient with a kidney graft in the pelvic cavity...
June 16, 2018: European Urology Focus
https://www.readbyqxmd.com/read/29921512/a-phase-ii-evaluation-of-sunitinib-in-the-treatment-of-persistent-or-recurrent-clear-cell-ovarian-carcinoma-an-nrg-oncology-gynecologic-oncology-group-study-gog-254
#13
John K Chan, William Brady, Bradley J Monk, Jubilee Brown, Mark S Shahin, Peter G Rose, Jae-Hoon Kim, Angeles Alvarez Secord, Joan L Walker, David M Gershenson
OBJECTIVES: To determine the efficacy and tolerability of sunitinib in recurrent or persistent clear cell ovarian cancer patients. METHODS: All patients had one or two prior regimens with measurable disease. Tumors were at least 50% clear cell histomorphology and negative for WT-1 antigen and estrogen receptor expression by immunohistochemistry. Sunitinib 50 mg per day for 4 weeks was administered in repeated 6-week cycles until disease progression or prohibitive toxicity...
June 16, 2018: Gynecologic Oncology
https://www.readbyqxmd.com/read/29920108/effects-of-linker-modification-on-tumor-to-kidney-contrast-of-68ga-labeled-psma-targeted-imaging-probes
#14
Hsiou-Ting Kuo, Jinhe Pan, Zhengxing Zhang, Joseph Lau, Helen Merkens, Chengcheng Zhang, Nadine Colpo, Kuo-Shyan Lin, Francois Benard
68Ga-PSMA-11 is currently the most popular prostate-specific membrane antigen (PSMA) radioligand used in the clinic to detect prostate cancer and metastases. However, the high uptake of 68Ga-PSMA-11 in kidneys can create halo-artifacts resulting in lower detection sensitivity for lesions adjacent to the kidneys. In this study, we developed two 68Ga-labeled PSMA-targeted tracers, 68Ga-HTK01166 and 68Ga-HTK01167, based on 68Ga-PSMA-617 with the goal of improving tumor-to-kidney ratio compared to 68Ga-PSMA-11...
June 19, 2018: Molecular Pharmaceutics
https://www.readbyqxmd.com/read/29917289/fh-inactivation-in-hereditary-leiomyomatosis-and-renal-cell-cancer-is-synthetic-lethal-with-ferroptosis-induction
#15
Michael John Kerins, John Milligan, James Akira Wohlschlegel, Aikseng Ooi
Hereditary leiomyomatosis and renal cell cancer (HLRCC) is a hereditary cancer syndrome characterized by inactivation of the Krebs cycle enzyme fumarate hydratase (FH). HLRCC patients are at a high risk of developing kidney cancer of type 2 papillary morphology that is refractory to current radio-, immuno-, and chemo- therapies. Hence, an effective therapy for this deadly form of cancer is urgently needed. Here we show that FH inactivation (FH-/- ) proves synthetic lethal with inducers of ferroptosis, an iron-dependent and nonapoptotic form of cell death...
June 19, 2018: Cancer Science
https://www.readbyqxmd.com/read/29916564/-chronicity-and-rehabilitation-in-general-medicine-and-geriatry
#16
Ciro Esposito
OBJECTIVES: The prevalence of chronic degenerative diseases such as diabetes, chronic kidney disease, obesity, cancer is increasing and comorbidity is more frequent in older age. The elderly patients with chronic degenerative diseases experience more acute complications and hospitalizations and poorer quality of life compared to elderly patients without chronic diseases. Furthermore it is widely acknowledged that an acute care model is inappropriate for patients with chronic conditions...
February 2018: Giornale Italiano di Medicina del Lavoro Ed Ergonomia
https://www.readbyqxmd.com/read/29915691/establishment-of-a-12-gene-expression-signature-to-predict-colon-cancer-prognosis
#17
Dalong Sun, Jing Chen, Longzi Liu, Guangxi Zhao, Pingping Dong, Bingrui Wu, Jun Wang, Ling Dong
A robust and accurate gene expression signature is essential to assist oncologists to determine which subset of patients at similar Tumor-Lymph Node-Metastasis (TNM) stage has high recurrence risk and could benefit from adjuvant therapies. Here we applied a two-step supervised machine-learning method and established a 12-gene expression signature to precisely predict colon adenocarcinoma (COAD) prognosis by using COAD RNA-seq transcriptome data from The Cancer Genome Atlas (TCGA). The predictive performance of the 12-gene signature was validated with two independent gene expression microarray datasets: GSE39582 includes 566 COAD cases for the development of six molecular subtypes with distinct clinical, molecular and survival characteristics; GSE17538 is a dataset containing 232 colon cancer patients for the generation of a metastasis gene expression profile to predict recurrence and death in COAD patients...
2018: PeerJ
https://www.readbyqxmd.com/read/29915171/effects-of-immune-suppression-for-transplantation-on-inflammatory-colorectal-cancer-progression
#18
Imerio Angriman, Lucrezia Furian, Melania Scarpa, Matteo Fassan, Susan Morgan, Andrea Porzionato, Andromachi Kotsafti, Luca Saadeh, Cristina Silvestre, Raffaele De Caro, Amedeo Carraro, Umberto Tedeschi, Romeo Bardini, Paolo Rigotti, Massimo Rugge, Carlo Castoro, Ignazio Castagliuolo, Marco Scarpa
BACKGROUND: Ulcerative colitis patients and transplant recipients are at risk for colorectal cancer. Here, we show that immunosuppressive regimens for kidney transplants are associated with the progression of ulcerative colitis-related carcinogenesis. METHODS: We describe the case of a patient diagnosed with colorectal cancer in ulcerative colitis while on immunosuppressive therapy for a kidney transplant. The immunological microenvironment of the cancer and its mutational status were analyzed, and a mouse colon cancer model was created to replicate the unique clinical conditions...
June 19, 2018: Oncogenesis
https://www.readbyqxmd.com/read/29913911/buprenorphine-clinically-useful-but-often-misunderstood
#19
Stephen Butler
Background There are a number of false myths about buprenorphine based on unconfirmed animal data, even from isolated animal organs, and early clinical research. These myths came into textbooks on pharmacology and pain about 30 years ago and have been difficult to eradicate. Animal models of pain and pain relief are notoriously unreliable as predictors of human clinical effects. The fact is that in clinical practice there is NO bell-shaped dose-response curve, there is NO plateau on the dose-response curve, and there is NO antagonist effect from buprenorphine on other mu-opioid agonists...
December 29, 2017: Scandinavian Journal of Pain
https://www.readbyqxmd.com/read/29912582/biomarkers-of-aggressiveness-in-genitourinary-tumors-with-emphasis-on-kidney-bladder-and-prostate-cancer
#20
Alessia Cimadamore, Silvia Gasparrini, Matteo Santoni, Liang Cheng, Antonio Lopez-Beltran, Nicola Battelli, Francesco Massari, Francesca Giunchi, Michelangelo Fiorentino, Marina Scarpelli, Rodolfo Montironi
Over the last decade, the improvement in molecular techniques and the acquisition of genomic information has transformed and increased the quality of patient care and our knowledge of diseases. Areas covered: Protein expression levels in immunohistochemistry and molecular biomarkers are reported for their ability to predict recurrence, progression, development of metastases, or patient survival. In particular, for renal cell carcinoma, we take into consideration the biomarkers applicable to immunohistochemistry and with molecular and genetic analyses...
June 18, 2018: Expert Review of Molecular Diagnostics
keyword
keyword
52385
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"